A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2012
At a glance
- Drugs MDT 637 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 28 Sep 2012 Results were presented at the 8th Annual International Respiratory Syncytial Virus Symposium (RSV-2012), according to a MicroDose Therapeutx media release.
- 02 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 02 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.